Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: A case study

Rheumatology International

Volumn 32, Issue 8, 2012, Pages 2367-2370

  Lahmer, Tobias ^a   Knopf, Andreas ^a   Lanzl, Ines ^a   Heemann, Uwe ^a   Thuermel, Klaus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adalimumab; Neurosarcoidosis; Ocular sarcoidosis; Sarcoidosis; TNF alpha antagonist

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CASE REPORT; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHADENOPATHY; MALE; MULTISYSTEM SARCOIDOSIS; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; SARCOIDOSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; SARCOIDOSIS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84866234969     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1968-x     Document Type: Article

References (19)

1. Baughman RP, Lower EE, du Bois RM (2003) Sarcoidosis. Lancet 36:1111-1118
2. Thomas KW, Hunninghake GW (2003) Sarcoidosis. JAMA 289:3300-3303
3. Agostini C, Adami F, Semenzato G (2000) New pathogenetic insights into the sarcoid granuloma. Curr Opin Rheumatol 12:71-76
4. Tracey KJ (1994) Tumor necrosis factor alpha. The cytokine handbook, 2nd edn. Academic press, Ney York, pp 289-304
5. Pritchard C, Nadarajah K (2004) Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 63:318-320
6. Baughman RP, Costabel U, du Bois RM (2008) Treatment of sarcoidosis. Clin Chest Med 29:533-548
7. Ulbricht KU, Stoll M, Bierwirth J et al (2003) Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 48:3542-3543
8. Moller DR (2003) Treatment of sarcoidosis from a basic science point of view. J Intern Med 253:31-40
9. Baughman RP (2004) Pulmonary sarcoidosis. Clin Chest Med 25:521-530
10. Marangoni S, Argentiero V, Tavolato B (2006) Neurosarcoidosis: clinical description of 7 cases with a proposal for a new diagnostic strategy. J Neurol 253:488-495
11. Lower EE, Broderick JP, Brott TG et al (1997) Diagnosis and management of neurological sarcoidosis. Arch Int Med 157:1864-1868
12. Jabs DA, Johns CA (1986) Ocular involvement in chronic sarcoidosis. Am J Ophthalmol 102:297-301
13. Baughman RP, Bradley DA, Lower EE (2005) Infl iximab in chronic ocular inflammation. Int J Clin Pharmacol Ther 43:7-11
14. Doty JD, Mazur JE, Judson MA (2005) Treatment of sarcoidosis with infliximab. Chest 127:1064-1071
15. Baughman RP, Drent M, Kavuru M et al (2006) Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 174(7):795-802 (Epub 2006 July 13)
16. Moravan M, Segal BM (2009) Treatment of CNS sarcoidosis with infliximab and mycophenolate mofetil. Neurology 27(72):337-340
17. Utz JP, Limper AH, Kalra S et al (2003) Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124:177-185
18. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC et al (2006) Development of sarcoidosis during etanercept therapy. Arthritis Rheum 55:817-820
19. Skoie IM, Wildhagen K, Omdal R (2010) Development of sarcoidosis following etanercept treatment: a report of three cases. Rheumatol Int [Epub ahead of print]